Biochemical bases of the organoprotective properties of metformin

Author:

Teplova A. S.1ORCID,Titova V. V.1ORCID,Tenchurina A. I.1ORCID

Affiliation:

1. Federal State Autonomous Educational Institution of Higher Education «N.I. Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian Federation

Abstract

Metformin is recognized as the "gold standard" for the treatment of type 2 diabetes mellitus (DM2). Its hypoglycemic properties are realized by reducing insulin resistance, contributing to the utilization of glucose in liver cells, muscles and adipose tissue; suppression of gluconeogenesis in the liver. Due to the wide range of biochemical targets of its pharmacological action, the scientific community actively discusses the use of metformin as an organoprotective drug. Now, the beneficial effect of metformin on the course of neuropathy, diseases of the cardiovascular system, normalization of the composition and metabolic activity of the intestinal microbiota, the course of metabolically associated fatty liver disease has already been proven, the nephroprotective effect has also been proven, and the study of the anti-oncogenic properties of metformin continues. The number of publications devoted to research on the positive effects of metformin on various organs and systems is actively increasing, and data on the identification of new effects are regularly published. The purpose of this literature review is to analyze the pleiotropic effects of metformin at the level of biochemical interactions for a more detailed understanding of the principles of their implementation.

Publisher

Focus Endocrinology

Reference42 articles.

1. Journal of Cell Biology & Cell Metabolism. Nibedita Rath. Role of Metformin in Infection. Pub. date: Feb 03, 2020 DOI:10.24966/CBCM-1943/100019

2. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Medical Management of Hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy // Dabetes Care. — 2009. — Vol. 32. — P. 1-11.

3. Dedov I., Shestakova M., Mayorov A., Mokrysheva N., Andreeva E., Bezlepkina O., et al. 11th Edition. Diabetes mellitus. 2023;26(2S):1-157. (In Russ.) https://doi.org/10.14341/DM13042

4. Полубояринова И.В., Фадеев В.В. Новый взгляд на эффекты метформина // Терапия. - 2016. - №1. - C. 97-104.

5. Mel'nikova O.G. Britanskoe prospektivnoe issledovanie sakharnogo diabeta (UKPDS) - rezul'taty 30-letnego nablyudeniya bol'nykh sakharnym diabetom 2 tipa. Diabetes mellitus. 2008;11(4):91-92. https://doi.org/10.14341/2072-0351-5599

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3